Opportunities & Challenges in Characterizing Crystallinity in ASD Intermediates & DP Formulations
Contemporary Opportunities and Challenges in Characterizing Crystallinity in Amorphous Solid Dispersion Intermediates and Drug Product Formulations
11 - 12 PM ET, Thursday, 28 September
Presented by the Characterization of Amorphous Solid Dispersion Group
Sponsored by the Analytical Leadership Group
- Matthew Lamm, Merck & Co., Inc.
- Lili Feng, Bristol Myers Squibb
- Frank Theil, AbbVie
- Paul Stroud, Eli Lilly
The webinar will provide a brief overview of the IQ Consortium's Working Group on the Characterization of Amorphous Solid Dispersions and discuss the key themes in the group's recent published whitepaper highlighting the challenges and opportunities in characterizing potential crystallinity in these systems with respect to technical and regulatory considerations. Finally, a panel of comprised of members from the working group will address questions submitted by the webinar participants.
This webinar is open to the public. Membership in the IQ Consortium is not required for registration.
Is your organization a member of IQ? Check here: https://iqconsortium.org/about/current-members/